메뉴 건너뛰기




Volumn 61, Issue 1, 2012, Pages 73-77

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: Final results of a randomized, controlled, phase II study (protocol 004)

Author keywords

antiretroviral therapy; HIV 1; integrase inhibitor; MK 0518; raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; EFAVIRENZ; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; TENOFOVIR; TRIACYLGLYCEROL; VIRUS RNA;

EID: 84865704490     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318263277e     Document Type: Article
Times cited : (22)

References (21)
  • 1
    • 0034723439 scopus 로고    scopus 로고
    • Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
    • Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
    • (2000) Science , vol.287 , pp. 646-650
    • Hazuda, D.J.1    Felock, P.2    Witmer, M.3
  • 2
    • 84865706397 scopus 로고    scopus 로고
    • Merck & Co Inc Accessed December, 2011
    • Merck & Co, Inc. Prescribing Information for ISENTRESS (Raltegravir) Tablets; 2007. Available at: http://www.merck.com/product/usa/pi-circulars/i/ isentress/isentress-pi.pdf. Accessed December, 2011.
    • (2007) Prescribing Information for ISENTRESS (Raltegravir) Tablets
  • 3
    • 33845366857 scopus 로고    scopus 로고
    • Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
    • Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 509-515
    • Markowitz, M.1    Morales-Ramirez, J.O.2    Nguyen, B.Y.3
  • 4
    • 34748860363 scopus 로고    scopus 로고
    • Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: Results of a 48-week controlled study
    • Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007;46:125-133.
    • (2007) J Acquir Immune Defic Syndr , vol.46 , pp. 125-133
    • Markowitz, M.1    Nguyen, B.Y.2    Gotuzzo, E.3
  • 5
    • 70350558421 scopus 로고    scopus 로고
    • Sustained antiretroviral efficacy of raltegravir as part of combination antiretroviral therapy in treatment-naive HIV-1 infected patients: 96-week data
    • Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral efficacy of raltegravir as part of combination antiretroviral therapy in treatment-naive HIV-1 infected patients: 96-week data. J Acquir Immune Defic Syndr. 2009;52:350-356.
    • (2009) J Acquir Immune Defic Syndr , vol.52 , pp. 350-356
    • Markowitz, M.1    Nguyen, B.Y.2    Gotuzzo, E.3
  • 6
    • 69449101785 scopus 로고    scopus 로고
    • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaïve patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial
    • Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatmentnaïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
    • (2009) Lancet , vol.374 , pp. 796-806
    • Lennox, J.L.1    Dejesus, E.2    Lazzarin, A.3
  • 7
    • 77956646683 scopus 로고    scopus 로고
    • Raltegravir-based compared to efavirenz-based regimens in treatment-naive HIV-1 infected patients: Efficacy, durability, subgroup, safety, and metabolic analyses through 96 weeks of follow-up
    • Lennox JL, DeJesus E, Berger DS, et al. Raltegravir-based compared to efavirenz-based regimens in treatment-naive HIV-1 infected patients: efficacy, durability, subgroup, safety, and metabolic analyses through 96 weeks of follow-up. J Acquir Immune Defic Syndr. 2010;55:39-48.
    • (2010) J Acquir Immune Defic Syndr , vol.55 , pp. 39-48
    • Lennox, J.L.1    Dejesus, E.2    Berger, D.S.3
  • 8
    • 80052905594 scopus 로고    scopus 로고
    • Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK
    • Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807-816.
    • (2011) Clin Infect Dis , vol.53 , pp. 807-816
    • Rockstroh, J.K.1    Lennox, J.L.2    Dejesus, E.3
  • 9
    • 34147136222 scopus 로고    scopus 로고
    • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: A phase II randomized controlled trial
    • Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatmentexperienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.
    • (2007) Lancet , vol.369 , pp. 1261-1269
    • Grinsztejn, B.1    Nguyen, B.Y.2    Katlama, C.3
  • 10
    • 77949381837 scopus 로고    scopus 로고
    • Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study
    • Gatell JM, Katlama C, Grinsztejn B, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr. 2010;53:456-463.
    • (2010) J Acquir Immune Defic Syndr , vol.53 , pp. 456-463
    • Gatell, J.M.1    Katlama, C.2    Grinsztejn, B.3
  • 11
    • 47949120697 scopus 로고    scopus 로고
    • Raltegravir with optimized background therapy for resistant HIV-1 infection
    • Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Eng J Med. 2008; 359:339-354.
    • (2008) N Eng J Med , vol.359 , pp. 339-354
    • Steigbigel, R.T.1    Cooper, D.A.2    Kumar, P.N.3
  • 12
    • 47949114939 scopus 로고    scopus 로고
    • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    • Cooper D, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Eng J Med. 2008;359:355-365.
    • (2008) N Eng J Med , vol.359 , pp. 355-365
    • Cooper, D.1    Steigbigel, R.T.2    Gatell, J.M.3
  • 13
    • 75749107023 scopus 로고    scopus 로고
    • Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials
    • Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis. 2010;50:605-612.
    • (2010) Clin Infect Dis , vol.50 , pp. 605-612
    • Steigbigel, R.T.1    Cooper, D.A.2    Teppler, H.3
  • 14
    • 84865759062 scopus 로고    scopus 로고
    • Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naïve HIV-1 infected patients: 144-week data
    • July 20 Cape Town, South Africa
    • Gotuzzo E, Nguyen BY, Markowitz M, et al. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naïve HIV-1 infected patients: 144-week data. Presented at: 5th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 20, 2009; Cape Town, South Africa.
    • (2009) 5th IAS Conference on HIV Pathogenesis Treatment and Prevention
    • Gotuzzo, E.1    Nguyen, B.Y.2    Markowitz, M.3
  • 15
    • 77954716682 scopus 로고    scopus 로고
    • Sustained antiretroviral efficacy of raltegravir after 192 weeks of combination ART in treatmentnaïve HIV-1 infected patients
    • February 17 San Francisco, CA
    • Gotuzzo E, Nguyen BY, Markowitz M, et al. Sustained antiretroviral efficacy of raltegravir after 192 weeks of combination ART in treatmentnaïve HIV-1 infected patients. Presented at 17th Conference on Retrovirus and Opportunistic Infection; February 17, 2010; San Francisco, CA.
    • (2010) 17th Conference on Retrovirus and Opportunistic Infection
    • Gotuzzo, E.1    Nguyen, B.Y.2    Markowitz, M.3
  • 16
    • 63649139412 scopus 로고    scopus 로고
    • Exacerbation of depression associated with starting raltegravir: A report of four cases
    • Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22: 1890-1892.
    • (2008) AIDS , vol.22 , pp. 1890-1892
    • Harris, M.1    Larsen, G.2    Montaner, J.S.3
  • 17
    • 79951713523 scopus 로고    scopus 로고
    • Long-term safety from the raltegravir clinical development program
    • Teppler H, Brown DD, Leavitt RY, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9:40-53.
    • (2011) Curr HIV Res , vol.9 , pp. 40-53
    • Teppler, H.1    Brown, D.D.2    Leavitt, R.Y.3
  • 18
    • 78650825831 scopus 로고    scopus 로고
    • Severe raltegravir-associated rhabdomyolysis: A case report and review of the literature
    • Croce F, Vitello P, Dalla Pria A, et al. Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS. 2010;21:783-785.
    • (2010) Int J STD AIDS , vol.21 , pp. 783-785
    • Croce, F.1    Vitello, P.2    Dalla Pria, A.3
  • 19
    • 0345064200 scopus 로고    scopus 로고
    • Combination antiretroviral therapy and the risk of myocardial infarction
    • The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
    • The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
    • (2003) N Engl J Med , vol.349 , pp. 1993-2003
  • 20
    • 0042768569 scopus 로고    scopus 로고
    • Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population
    • Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37:292-298.
    • (2003) Clin Infect Dis , vol.37 , pp. 292-298
    • Saves, M.1    Chene, G.2    Ducimetiere, P.3
  • 21
    • 0042832397 scopus 로고    scopus 로고
    • Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
    • Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
    • (2003) Clin Infect Dis , vol.37 , pp. 613-627
    • Dube, M.P.1    Stein, J.H.2    Aberg, J.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.